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Abstract Different therapeutic options for the management of prostate cancer (PC) have been developed, and some are 
successful in providing crucial improvement in both survival and quality of life, especially in patients with metastatic 
castration-resistant PC. In this scenario, diverse combinations of radiopharmaceuticals (for targeting bone, cancer cells 
and receptors) and nuclear medicine modalities (e.g. bone scan, SPECT, SPECT/CT, PET and PET/CT) are now 
available for imaging bone metastases. Some radiopharmaceuticals are approved, currently available and used in the 
routine clinical setting, while others are not registered and are still under evaluation, and should therefore be considered 
experimental. On the other hand, radiologists have other tools, in addition to CT, that can better visualize bone 
localization and medullary involvement, such as multimodal MRI. In this review, the authors provide an overview of 
current management of advanced PC and discuss the choice of diagnostic modality for the detection of metastatic 
skeletal lesions in different phases of the disease. In addition to detection of bone metastases, the evaluation of response 
to therapy is another critical issue, since it remains one of the most important open questions that a multidisciplinary 
team faces when optimizing the management of PC. The authors emphasize the role of nuclear modalities that can 
presently be used in clinical practice, and also look at future perspectives based on relevant clinical data with novel 
radiopharmaceuticals. 
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Introduction 
 
In recent years, prostate cancer (PC) has been an active field of research in terms of biology, 
diagnostic imaging and drug development. In particular, the widespread application of new 
diagnostic technologies is offering various strategies to detect bone metastases (BMT) and assess 
treatment response in patients with advanced disease. Therefore, the approach to the management of 
PC, particularly in patients with high-risk PC (i.e. at least one of the following characteristics: PSA 
>20 ng/mL, Gleason score (GS) ≥8, clinical stage T2c–3a in accordance with D’Amico 
classification) and with skeletal metastases, has rapidly changed. The relevance of skeletal 
metastases in patients affected by PC is well known, and their impact on survival, life expectancy 
and quality of life has been reported by many authors [1–6]. Until a few years ago, patients with 
skeletal metastases were treated only palliatively. Conversely, today the introduction of new drugs 
has provided both a delay in skeleton-related events (SREs) and a significant improvement in 
overall survival (OS) [7–18]. 
Knowledge of the number and the pattern of BMT is essential to choose the correct therapy and 
allow proper evaluation of tumour response. Several radiopharmaceutical agents are currently 
available and used in different diagnostic modalities, including bone scan (BS), SPECT, 
SPECT/CT, PET and PET/CT. The main challenges at present are to determine the best option to 
detect BMT in different phases of the disease and to measure changes in radiopharmaceutical 
uptake as an early sign of response to treatment or progression. National and international clinical 
guidelines still recommend traditional BS with 99mTc-phosphonates as the standard method for 
studying BMT, and only a few, in certain situations, suggest other nuclear medicine approaches, 
such as 18F-fluoride and 11C/18F-choline PET/CT, which have been validated in several clinical 
studies, and are registered and available for clinical use [19–21]. Thus, the time has come to 
stimulate open discussion about the role of different modalities based on bone-targeting agents 
(99mTc-phosphonate BS, 99mTc-phosphonate SPECT/CT and 18F-fluoride PET/CT) and cancer-
targeting agents (11C/18F-choline PET/CT, 18F-FDG PET/CT) compared with the diagnostic 
options offered by radiology (e.g. CT and MRI). In addition, rapid progress in radiopharmacy 
research has led to the development of new receptor-targeting radiopharmaceutical agents such as 
68Ga/18F-PSMA, which has been the subject of intense clinical assessment in several European 
countries with very promising results. Therefore, this field is a fertile area of discussion and debate. 
We review the current status regarding the management of BMT in PC patients by summarizing the 
most relevant achievements from pathogenesis to treatment. New scientific knowledge on the 
physiopathology of BMT formation, markers of bone remodelling, main diagnostic strategies and 
novel treatments for advanced disease are presented. Most discussion is focused on analysis of the 
advantages and disadvantages offered by currently available diagnostic tools in nuclear medicine 
and radiology, and their current position in the diagnostic work-up of patients with skeletal 
metastatic disease. 68Ga/18F-PSMA, 18F-FACBC and 18F-bombesin are still considered as 
experimental radiopharmaceutical agents, and therefore are not fully available in clinical practice or 
are already registeredby regulatory authorities.However, in the present manuscript, we will give 
more attention to 68Ga-PSMA that represents the most interesting tracers up to now. Pathogenesis 
of bone metastases BMT are observed in approximately 3 – 6 % of patients with newly diagnosed 
PC, and 11.5 % of patients who are metastasis-free at baseline develop BMT after about 2 years 
of follow-up [10, 22]. In advanced stage PC, skeletal involvement is present in about 90 % of 
patients with metastatic disease [23, 24]. From autopsy data, 35 % of patients with advanced PC 
will develop haematogenous metastases and, in 90 % of such patients, the metastases will be 
localized in the bone [25, 26]. However, there is a wide range in reported incidence (between 35 % 
and 70 %) that varies depending on the study characteristics, population and follow-up period [27–
29]. Given the increasing sensitivity of imaging modalities such as PET/CT and improvement in 
survival using new therapies, the number of PC patients with metastases at diagnosis is likely to 
increase and the visceral/skeletal ratio is likely to change [30]. BMT is a multistep process and its 
complex pathogenesis is not yet fully clarified. High bone turnover induced by androgen ablation is 
a predisposing condition to the homing and dissemination of tumour cells to bone marrow [31]. In 
animal models, there is evidence that PC cells home to sites of osteoblast-rich niches at an early 
stage [32]. The osteoblastic lesion is the result of releasing osteoblast-promoting factors from PC 
cells, and it has recently been demonstrated that osteocytes are also critical mediators in the bone 
metastatic niches. Therefore, targeting bone turnover at an early stage may be a useful strategy for 
preventing BMT in PC patients. BMT in PC are usually defined as Bosteoblastic^ by conventional 
plain radiography. However, recent studies have shown a high heterogeneity of lesions with 
synchronous osteolysis and blastic lesions [33]. Histomorphometric studies have shown that blastic 
lesions are mixed in nature with increased activities of both osteoblasts and osteoclasts [34]. The 
under-mineralized woven bone and the osteopenic/osteolytic component of BMT may contribute to 
the skeletal frailty observed in PC patients with metastases, even in those with dense metastatic 
lesions [35].BMT most commonly affect the axial skeleton and pelvis, and patients with confined 
disease in the vertebrae have a better prognosis. Several authors have attempted to correlate the 
extent of skeletal metastatic involvement, number of metastases and distribution with survival of 
patients affected by advanced PC [8, 14, 16]. For example, patients with metastatic castration-
resistant PC (mCRPC) with a higher number of BMT (more than five) showed shorter progression-
free survival and OS than those with fewer than five lesions (HR 2.0, 95 % CI 1.7 – 2.4) [17]. 
Moreover, BMT can worsen the quality of life and survival through an increased risk of 
complications. The term SRE is a composite endpoint for research purposes used to group 
complications such as fractures and/or spinal cord compression that require radiotherapy and pre-
emptive bone surgery. Pathological fractures are common, and the commonest sites for fractures are 
the vertebral bodies and long bones. The most serious complications are impingement 
of the spinal cord, impeded anabolism due to mandatory castration therapy, and deterioration of 
general status that are the leading causes of hospitalization and death. 
In patients with mCRPC, the rate of SRE has been reported to be 44.2 % after 15 months in the 
placebo arm of a randomized clinical trial of zoledronic acid [7]. Oster et al. found that more than 
half (51.7 %) of PC patients experience an SRE during follow-up [13]. Interestingly, there are no 
differences in terms of incidence of SRE and median survival time after SRE between osteoblastic 
and osteolyticBMT. However, pathological fractures and hypercalcaemia are slightly more frequent 
in osteolytic than osteoblastic BMT (52 % vs. 25 %, respectively). Conversely, spinal cord 
compression is more frequent in osteoblastic than for lytic BMT (8 % vs. 3 %, respectively). 
Radiation or surgery to bone are used at similar rates for bothtypes of bone lesions [36]. Between 
1998 and 2010, the rate of SRE in PC patients decreased from 18% to 15.4 %, and SREassociated 
mortality decreased from 8.5 % to 4.7 % [37]. The SEER-Medicare dataset (1999 – 2009) shows 
that the HR of PC-specific mortality associated with SRE ranges from 1.07 to 1.31, and is also 
associated with spinal cord compression and pathological fractures [10–12, 15]. More recently, 
other researchers have investigated whether novel molecular approaches might provide additional 
prognostic information in patients with BMT. Indeed, it has been shown that BMT in mCRPC 
patients express higher levels of androgen receptor (AR) splice variants, such as AR-V7 and 
AR567e, than BMT in hormone-naive patients. The overexpression of AR variants is usually 
correlated with poorer prognosis and resistance to endocrine therapies [38]. 
 
Current treatments 
 
Nowadays, physicians can choose among several effective alternative treatments for mCRPC. 
Adequate management of patients with BMT should guarantee a correct balance of efficacy, 
symptom control and prevention of disease complications. Both chemotherapy with docetaxel and 
cabazitaxel [39–44], and novel endocrine therapies such as abiraterone acetate and enzalutamide 
[45–47] have been shown to have a favourable impact on survival in mCRPC. More recently, 
docetaxel has been shown to improve life expectancy of hormone-naive patients with high risk and 
high tumour burden when combined with androgen deprivation treatments [42]. Up to now, 
although several beta emitters are available for palliative treatment of BMT, only the alpha emitter 
223Ra chloride has demonstrated a survival advantage in symptomatic mCRPC patients, with 
limited myelotoxicity [48]; this drug is now recommended in both chemonaive patients and patients 
who have received docetaxel when symptomatic bone disease is present [48, 49]. 
The appropriate algorithm for use of available drugs is still an area of open discussion. If palliation 
is the main purpose, bone-modifying agents including bisphosphonates and the inhibitor of the 
RANK/RANKL pathway, denosumab, can be used to reduce the risk of SRE and improve the bone 
pain control in symptomatic patients [50], although denosumab has been shown to be superior to 
zoledronic acid in delaying and preventing SREs. None of these agents, however, is associated with 
improvement in OS. External beam radiotherapy is also an effective palliative treatment for control 
of pain due to BMT. It can achieve significant clinical results in 60 – 80 % of patients, with up to 
half of patients obtaining complete pain relief at the treated site [51, 52]. Numerous prospective 
randomized trials, meta-analyses and systematic reviews have shown similar pain relief outcomes 
with single-fraction schedules (8 Gy) compared with longer courses of palliative radiotherapy in 
BMT from a variety of primary malignancies [52–54]. The available evidence supports the use of 
single-fraction radiotherapy as a standard for all uncomplicated BMT from PC, because of its 
positive effects on several types of endpoints (e.g. response rates, responseduration, re-treatment 
rates, toxicity, cost-effectiveness [55–57]. 
 
Methods to study bone metastases 
 
Clinical evaluation and PSA 
 
Pain is a common symptom in PC patients with skeletal metastases,with a prevalence of about 75 % 
[58]. Recognizing the cause of pain is a prerequisite for a correct and rational therapeutic approach 
to improve and/or preserve quality of life, avoid or delay SREs and, whenever possible, to prolong 
survival [59]. Patient examination and administration of appropriate questionnaires is needed using 
validated and standardized tools, such as the visual analogue scale and World Health Organization 
score [60]; a multidisciplinary approach to evaluate patients and establish the optimal approach 
should be implemented at the early stages of disease. At present, prostrate-specific antigen (PSA) is 
commonly used for detecting tumour presence, extension and growth. PSA is also considered for 
monitoring chemotherapy treatments, although for drugs targeting BMT it is reliable since it is a 
marker for tumour, and not bone remodelling. It is generally accepted that a 50 % decrease in PSA 
levels compared with initial values is predictive of good metabolic response, and is often associated 
with better survival [61]. However, even in this setting, changes in PSA can show unexpected 
trends [62]. Recent recommendations from the Prostate Cancer Clinical Trials Working Group 
(PCWG2 and PCWG3) of the American Society of Clinical Oncology define PSA progression, 
during or after therapy, as the date that a 25 % or greater increase and an absolute increase of 2 
ng/mL or more from when nadir is documented and confirmed by a second value obtained ≥3 
weeks later [30, 63]. 
 
Markers of bone turnover 
 
Continuous skeletal remodelling by osteoclast bone resorption and osteoblast bone formation can be 
quantified using serum and urinary biochemical parameters, or so-called markers of bone turnover. 
BMT are characterized by high focal bone turnover with increased levels of osteolysis and/or 
osteogenesis. For this reason, biochemical markers of bone remodeling might be an ideal tool to 
monitor progression of osteolytic or osteoblastic metastasis and/or response to treatment. At 
present, serum procollagen type I N-propeptide, s-PINP, and serum C-terminal telopeptide of type I 
collagen, s-CTX, are recommended as gold standard markers of bone formation and bone 
resorption, respectively [12]. The clinical utility of bone markers as diagnostic indicators of bone 
metastatic disease and as prognostic indicators has been extensively examined. Several studies have 
revealed an association between bone turnover marker and presence or progression of skeletal 
metastases from PC [64–67]. Bone alkaline phosphatase (ALP) had the highest diagnostic accuracy 
(72 % sensitivity, 88 % specificity) and PINP the highest diagnostic specificity (92 %) [67]. 
Retrospective analyses of data from the phase III trials of zoledronic acid in patients with mCRPC 
and BMT showed that both baseline and on-study elevation in bone marker levels, in particular 
NTX and bone ALP, were associated with increased risks of SRE, disease progression and death 
[68–70]. A high baseline level of urinary NTX (>180 nmol/mmol creatinine) was associated with a 
more than 2.5-foldincrease in the risk of death (RR 2.58, 95 % CI 1.92 – 3.47) compared with a low 
baseline level of NTX (<55 nmol/ mmol creatinine), and an increase in baseline bone ALP was 
associated with a 4 % increase in the risk of death and SRE per 200 UI/L increase [68–70]. 
Recently, bone ALP velocity (>6.3 UI/L/year) has been found to be an independent predictor of OS 
in patients with mCRPC. A fivefold increase in the risk of death was observed among mCRPC 
patients with rapid bone ALP velocity (HR 5.11< 95 % CI 2.24 – 11.67) [71]. Moreover, CTX or 
NTX in association with PINP have prognostic significance as bone markers [72]. However, in 
cancer patients serum or urinary levels of bone turnover markers may be high for several 
concomitant causes such as age, vitamin D deficiency and adjuvant hormone therapy in addition to 
BMT, and it is impossible to distinguish the contribution of the different components that elevate 
the levels of bone markers [73]. 
In summary, the current clinical utilization of bone turnover markers for diagnosis, prognosis and 
monitoring therapy in PC patients with skeletal metastases remains of high interest, but cannot be 
recommended at present. There is, however, an objective need for harmonization, standardization 
and common reference ranges for reproducible significance of bone biomarkers in routine practice 
[74–76]. 
 
Radiological imaging 
 
Conventional plain radiography, often in association with 99mTc-diphosphonate BS, CT and MRI, 
can be used in the assessment of prostatic bone disease, with varying results, as confirmed by data 
in the literature (Table 1). Plain radiography was historically the first imaging modality available 
for assessing bone and BMT. Plain radiography is readily available and usually easy for the patient. 
Although not particularly sensitive (30 – 75 % of trabecular bone must be destroyed before osseous 
destruction is detectable on a conventional plain radiograph), plain radiography does give an 
overview of the status of a particular bone segment, and in the absence of Bred flag^ symptoms, it 
is a good preliminary investigation. In addition, it is simple and cost effective, especially in 
symptomatic patients, and allows the assessment of potential complications such as pathological 
fractures. However, neither systematic bone screening nor evaluation of treatment response of BMT 
by conventional plain radiography are currently used in clinical practice because of their low 
diagnostic accuracy; indeed, radiographic signs of therapeutic response of bone lesions (peripheral 
sclerosis, lesion filling, and condensation) are delayed by several months, ambiguous, or absent 
despite clinical improvement [86, 87]. Peripheral sclerosis is observed only in osteolytic lesions, 
which are observed in only 10 % of patients with bone metastatic PC. Conversely, condensation is 
more frequent in mixed or osteoblastic lesions. CT is well suited to bone imaging. The availability 
of CT has increased greatly in recent years and the speed and quality of image reconstruction has 
been substantially enhanced. CT allows finely detailed assessment of osseous architecture, 
including the cortex and trabecular framework, and detects much smaller areas of trabecular 
destruction/invasion than visible by plain radiography alone. CT is also particularly helpful in 
assessing areas that can be difficult to visualize by plain radiography, such as the sacrum. For 
evident radioprotection reasons, CT targets a particular portion of the body and is not used for 
whole-body (WB) bone screening in clinical applications, although in some situations it is routinely 
employed. Moreover, CT scans are limited in their ability to assess therapeutic response because 
bone structure rarely normalizes even with completely effective therapy. The appearance of new or 
worsening bone sclerosis on CT in patients is occasionally and erroneously classified as disease 
progression (CT flare response) by inexperienced radiologists. RECIST criteria (v. 1.1) allow 
individual osteolytic or mixed osteolytic/osteoblastic metastases to be measured if there is a 
soft-tissue component, but diffuse disease and osteoblastic BMT are considered non-evaluable [88, 
89]. Furthermore, other observations (e.g. lack of change, appearance of new sclerotic areas) should 
be considered more cautiously and should not be taken into account in evaluation of response. 
Plain radiography and CT detect neoplastic bone lesions at a late stage, i.e. weeks or months after 
the appearance of tumour cells within the bone marrow, because they rely on the activation of bone 
cells – osteoblasts and osteoclasts – to detect lesions. MRI is sensitive to early changes in bone 
marrow that precede the osteoclastic/osteoblastic response of the bone matrix to tumour infiltration 
before bone trabeculae or cortices are affected by disease. The superiority of MRI for detection 
of BMT over both plain radiography and CT (often as Baddons^ to bone scintigraphy) has been 
widely demonstrated (Table 1). The availability of the technique, its repeatability, lack of 
irradiation and its ability to provide WB evaluation have contributed to the development of MRI as 
the tool of choice for detection and follow-up of BMT. As an adjunct to conventional T1-weighted 
and STIR (short tau inversion recovery) acquisitions, diffusion-weighted imaging (DWI) sequences 
are also currently employed. DWI is able to detect changes in water diffusion that occur when 
normal fatty marrow is replaced with highly dense cellularity that restricts normal water movements 
among cell membranes. The advent of WB protocols with excellent image resolution and 
shortening of acquisition times, and the developmentWB DWIand Ball-organ^ capabilities, justify 
the increasing use of WB MRI at many centres [79, 90]. DWI provides morphological (qualitative) 
and functional (quantitative) information on BMT. Qualitatively, reconstructed maximum intensity 
projection (MIP) or multi-parametric projection (MPR) images of DWI, covering the whole body or 
only the central skeleton, provide an easy Bat a glance^ qualitative evaluation of tumour burden, 
and focus attention on areas that are difficult to analyse on anatomic images. Several pitfalls in the 
visual analysis of DWI images must be recognized. As DWI not only reflects the cellular load but 
also the water content of tissues, benign conditions such as degenerative joint diseases, fractures, 
postirradiation changes and benign tumours (angiomas) may show high signal intensity on DWI 
images. The technique may also present false-negative findings, mainly in sclerotic or calcified 
metastases. These shortcomings underline the need for a systematic correlation of DWI images with 
conventional sequences. In this regard, T1-weighted images are the most helpful, in particular when 
acquired using the 3D protocol, which has been demonstrated to increase the sensitivity in detection 
of lesions [91]. 
The technique also shows great promise for assessment of response.DWI is able to detect changes 
in water diffusion that occur after therapy as a result of changes in cellular density and loss of 
membrane integrity. The impeded water mobility observed in tumour tissue will decrease or 
disappear in relation to the loss of cellular integrity in response to treatment, for example owing to 
cellular necrosis. Comparison of consecutive examinations provides a rapid and generally 
nonambiguous qualitative evaluation of disease response or progression during therapy. DWI also 
allows the measurement of the apparent diffusion coefficient (ADC, units ×10−3 mm2/s), which 
provides functional (quantitative) assessment of tumour lesions. Generally, a tumour focus shows 
decreased ADC values in relation to increased cellularity and restricted mobility of protons in 
water. DWI is able to detect an increase in ADC in PC metastases treated with antiandrogen therapy 
as early as 1 month after treatment initiation [92, 93]. The effectiveness of ADC monitoring to 
predict the response of BMT to therapy is, however, controversial. The interpretation of changes in 
ADC values is indeed complex, mainly because of heterogeneity of both the tumour and response to 
treatment. Newer analysis methods (ADC parametric response or functional diffusion map) taking 
into account spatial information and tumour heterogeneity enable careful voxel-by-voxel follow-up 
of treatment-induced changes and evaluation of the proportion of tumour tissues in which 
significant changes occur [94]. These approaches seem to be able to detect very early changes 
(such as an increase in ADC) after treatment initiation. However, ADC can be used routinely only 
after optimization of hardware, sequences, signal analysis and definitive standardization of the 
acquisition method to improve the reliability of the results. Evaluation of reproducibility of ADC 
measurements is also a priority [94]. 
In conclusion, MRI (especially with the use of WB and  DWI acquisitions) has a well-established 
role for the detection of metastases, but evaluation of response to therapy is challenging due to the 
heterogeneity of disease and the mainly osteoblastic nature of metastases. Areas of sclerosis 
are often present at the time of diagnosis and may increase following treatment, even with other 
signs of response to treatment. When this occurs, neither DWI nor anatomic imaging appears to be 
useful in giving the correct response. In fact, the sclerotic lesion may actually appear larger and/ 
or the evaluation of its diffusion coefficient may be controversial. MRI appears to be a more 
reliable tool for: confirming stable disease when the size of measurable bone lesions remains 
unchanged and no new lesions are found; corroborating progressive disease when new lesions are 
seen or if a sclerotic lesion shows a new peripheral halo (hypointense on T1-weighted imaging and 
hyperintense on DWI as signs of increased cellularity and restricted diffusion) [79]. Therefore, the 
potential of MRI in evaluation of treatment response is still being studied, and only a limited 
amount of data are currently available [95] . 
 
Nuclear medicine imaging  
 
Nuclear medicine offers several options for the detection of BMT in PC patients: (a) BS as planar or 
tomographic imaging (i.e. single photon emission tomography, SPET) and (b) PET/ CT with 18F-
fluoride or 18F-FDG, 11C/18F-choline or 11C-acetate, 68Ga-PSMA, or 18F-FACBC. Each 
imaging technique has a specific mechanism of action in the detection of BMT due to differences in 
uptake and metabolism among the radiopharmaceuticals. Therefore, each technique is associated 
with different diagnostic performance that is mainly based on the type of skeletal lesion (i.e. 
osteoblastic vs. osteolytic vs. bone marrow invasion) [96–98]. At present, 11C-acetate, 68Ga-
PSMA and 18F-FACBC are still considered experimental radiopharmaceutical agents. These agents 
are not employed in routine clinical practice, and 11C-acetate, 68Ga-PSMA and 18F-FACBC are 
not discussed further in this review; however, the increasing data on 68Ga-PSMA in PC patients 
studied in several European countries has shown a promising role for this tracer in BMT detection, 
and this agent is discussed in the section New horizons in the detection of bone metastases and 
evaluation of response to treatment. Planar BS using 99mTc-diphosphonates is the standard 
technique for the detection of skeletal metastasis from PC as it is widely available, relatively 
inexpensive and highly sensitive. However, the mechanism of uptake of 99mTc to a suitable 
phosphonate that allows imaging of sites of blastic or mixed lesions, and not areas where a calcium 
deposit is lacking, limits the use of this radiopharmaceutical. For this reason, BS shows low 
specificity (falsely positive in benign lesions, prior trauma and arthritis) and flare phenomena. 
Therefore, an osteoblastic response that occurs as a result of bone healing/ flare response during 
systemic treatment can significantly alter its diagnostic performance and make clinical 
interpretation of scintigraphic findings very difficult. Moreover, in a large retrospective analysis, 
BMT were found in less than 1 % of patients with PSA <20 ng/mL, with a negative predictive value 
of 99.7 % [99]. Leucovet et al. found that in 100 patients with high-risk PC the sensitivity of BS 
increased from 80%to 86 % when it was added to targeted plain radiography [79]. However, 
although the introduction of tomographic imaging such as SPET and SPET/CT has overcome some 
of the limitations of BS, these modalities are not able to cover the entire body of the patient. An 
interesting possibility offered by BS is calculation of the BS index, which better reflects the extent 
of metastatic disease [100]. This approach is noteworthy since its measurement can be automated, 
although the technique has not shown value in routine clinical practice [101]. Even with persistently 
high costs, PET is an efficient modality for WB scanning in a reasonably short time.With the 
increasing availability of PET/ CT scanners and standardized acquisition protocols on different PET 
scanners, the possibility of obtaining more detailed and precise CT anatomic localizations of PET-
directed metabolic abnormalities of tumour lesions, especially in skeletal diseases, has become a 
clinical reality. Moreover, PET is able to provide quantitative and semiquantitative information by 
May, 2012 October, 2012 February,2013 Fig. 2 A 68-year-old man with prostate cancer treated 
by radical prostatectomy (pT3aN0Mx, Gleason score 10; positive margins and extracapsular 
invasion) and adjuvant radiotherapy in 2010. May 2012 In 2012, for biochemical recurrence of 
disease (PSA 15.55 ng/mL), he was staged by 18F-choline PET/CT that showed metastatic bone 
recurrence of disease. He was started on bicalutamide and LHRH analogues. October 2012 Due to 
a further increase in PSA (141 ng/mL after 4 months), 18F-choline PET/CT was repeated that 
showed progression of metabolic disease. Therefore, the attending oncologist suggested switching 
the treatment from androgen deprivation therapy to chemotherapy (docetaxel + prednisone). 
February 2013 After 4 months, PSA had reduced to 33.6 ng/mL and 18F-choline PET/CTshowed 
a good response to chemotherapy Eur J Nucl Med Mol Imaging (2016) 43:1546–1562 1555 using 
reproducible standardized quantification methods [102] that are useful for comparing serial 
examinations, especially before, during and after therapy. Nowadays, many radiopharmaceutical 
agents are available for PET/CT imaging, especially for the detection of BMT. 18F-Fluoride, a 
hydroxyapatite stabilizer, has the desirable characteristics of high and rapid bone uptake 
accompanied by very rapid blood clearance, which results in a high bone-to-background ratio in a 
short time. 18F/11C-Choline is a substrate of phospholipid metabolism which is usually enhanced 
in PC that is able to identify the presence of viable cancer tissue; promising results, especially for 
early detection of bone marrow infiltration, have been obtained. 18F-FDG is mainly used for 
definition of osteolytic lesions [57], but seems to be able to identify the presence of viable cells in 
osteoblastic ones, even if the majority of PC displays low glycolytic metabolic behaviour, which 
would suggest that its current use may not be optimal. Generally, high uptake of 18F-FDG is 
expected in prostate tumours that are poorly differentiated, hypoxic and have a high GS. However, 
it can be used to assess the extent of metabolically active castrate-resistant prostate disease. 
Table 2 summarizes the performance of each imaging modality. As shown, the median sensitivity of 
18F-fluoride PET/ CT is the highest in comparison to the other modalities for the detection of BMT 
in PC patients. However, it should be underlined that in many studies bone disease is often 
measured on follow-up imaging, such as CT, BS, or MRI, while histological assessment is not 
performed, mainly for ethical reasons. Conversely, both 11C-choline and 18F-choline PET/ CT 
show higher specificity than BS or 18F-fluoride PET/CT. This result can be linked to the different 
behaviour of 18F/11C-choline in osteoarticular disease. Moreover, as expected, 18F-FDG PET/CT 
has low sensitivity (between 56 % and 72 %) in the detection of BMT in patients with PC, although 
as suggested by several authors, and as mentioned above, it may occasionally be suitable for 
prostate imaging in a limited subset of selected patients with aggressive histology and poorly 
differentiated cancer [111, 117–119].  
Considering the areas of assessment of response to therapy, all of the above-mentioned metabolic 
methods may have value since their uptake is linked to the phenomenon of bone remodelling or to 
the metabolic activity of neoplastic cells. Most of the available data relate to BS as for decades this 
has been the most widely used modality to study skeletal lesions and still remains the most 
common. There are limited data regarding other modalities, even if there is a progressive increase in 
their use. The most recent data available in the literature demonstrate a role for radiolabelled 
choline PET/ CT in assessment of new hormonal therapies, such as enzalutamide [120, 121] or 
abiraterone acetate [122], and chemotherapy (i.e. docetaxel) [123]. The findings of radiolabelled 
choline PET/CT have been compared to PSA changes in order to determine the response to therapy. 
Choline PET/CT findings agree with PSA changes in the majority of patients with progressive 
disease, during and after therapy; on the contrary, PET/CT is able to identify only a moderate 
number of patients with partial or complete response to therapy. However, the disappearance of 
uptake does not always correlate with the disappearance of the cancer lesion since it could be due to 
the effect of a stable or nonmetabolically active focus. In contrast, the appearance of new areas of 
uptake does not always  correlate with certain progression due to the well-known phenomenon of 
flare reaction, whose correct interpretation in BS has been standardized. This issue is an open area 
of debate. 
 
New horizons in the detection of bone metastases and evaluation of response to treatment  
 
The majority of national and international guidelines for PC, such as EAU [20], AUA [124], ESMO 
[49] and NCCN [21], mainly recommend using PSA levels, BS and abdominopelvic CT to 
determine the presence of cancer and monitor treatment response. Moreover, in some recent clinical 
trials [41, 43, 46, 48, 90, 125], PSA, CT and BS have been used to evaluate tumour response to 
therapy in mCRPC patients. However, MRI has a greater ability to detect more skeletal lesions and 
earlier than CT; in addition, it is currently used as a Bproblemsolving^ technique when a lesion is 
reported as Bindeterminate^. However, MRI cannot be proposed as an alternative method for 
diagnosis of skeletal metastasis or for monitoring response to treatment because of its limited field 
of view (which can be overcome with WB MRI that is now available in a few centres) and restricted 
interpretation criteria when bone sclerosis is present at the metastatic site (such as RECIST). 
Although CT remains the most widespread imaging technique for detection of cancer, it is 
important to underline that RECIST criteria can be used for assessment of visceral metastases, but 
cannot be employed for evaluation of response to therapy in BMT, considering their anatomic 
features and biological behaviour. Therefore, the integration of PSA, other appropriate bone 
biomarkers such as ALP and morphological imaging with metabolic techniques can provide 
additional information that is reliable for monitoring changes occurring inside the tumour and bone 
structure. As already mentioned, BS continues to be used in clinical practice since it has advantages 
in terms of cost, availability and execution, even if it has low diagnostic specificity and cannot 
detect medullary and osteolytic lesions. The hybrid modality SPET/CTcan improve the accuracy of 
planar BS, but has a limited field of view like MRI and still suffers from the limitation of the poor 
specificity. 18F-Fluoride PET/CT can improve the sensitivity in detecting BMT, and also has other 
advantages, including better quality of images and shorter acquisition time. 18F/11CCholine and 
18F-FDG PET/CTare able to visualize both skeletal and nonskeletal metastases. In some studies, 
both metabolic radiopharmaceutical agents have been used to assess response to therapy [120–123, 
126, 127], but data are still preliminary. Table 3 summarizes the strengths and weaknesses of the 
currently employed radiological and nuclear medicine modalities in clinical practice for evaluation 
of bone lesions in patients with PC. The development of new receptor tracers, such as 68Ga- 
PSMA, has opened new approaches to the management of PC, although they are still experimental. 
The most significant advantages of 68Ga-PSMAPET/CTare the sensitive detection of lesions, even 
at low PSA levels (i.e. PSA <1 ng/mL), small lymph node metastases (primarily due to high 
radiotracer uptake) and central bone and liver metastases due to low background 
signal. However, PSMA imaging should be approached with caution because of the limited 
information in the form of published data. From current data, the detection rate of BMT with 68Ga-
PSMA is 37 % [96, 130–133] compared to 32.1 % with choline PET/CT [115, 134–138] (Tables 4 
and 5). However, continuing research will probably soon provide more information on the use of 
68Ga-PSMA (Figs. 1 and 2). Eur J Nucl Med Mol Imaging (2016) 43:1546–1562 1557 To date, on 
the basis of approved diagnostic instruments and radiopharmaceutical agents, we can summarize the 
evidence discussed above in a flow-chart to localize disease (BMT, monitor evolution and 
whenever possible obtain prognostic information). According to the site of recurrence, patients with 
PC can be classified as having bone-dominant (only skeletal involvement) or no bone-dominant 
disease (no skeletal, lymph node, visceral, or soft-tissue invasion; Fig. 3). Based on the extent of 
dissemination of disease, the most appropriate diagnostic tool to visualize BMT can be chosen 
based on disease grade (i.e. low grade, GS ≤7, or high grade, GS 8 – 10). Therefore, to detect 
lesions in bonedominant disease, all patients with PC who are candidates for bone-targeted 
therapies, such as 223Ra, could benefit from those techniques targeting bone modalities (BS and 
SPET or 18F-fluoride PET/CT). BS is still considered the standard method of choice, but could be 
replaced by 18F-fluoride PET/CT given its higher sensitivity. Moreover, since PET is always 
performed with CT (as PET/CT), the use of CT as a stand-alone examination for analysis of bone 
can be avoided. Additionally, MRI can be used to better characterize the structure of metastatic 
lesions and as a Bproblem-solving^ technique when an indeterminate lesion is found. In patients 
with bone-dominant disease and a GS ≥8 – 10, 18F-FDGPET/CTas a bone-targeting modality 
would be of value to obtain predictive information on both response to therapy and prognosis. Thus 
in patients with poorly differentiated disease, 18F-FDG PET/CT could be adopted. However, 
considering the limited utility of 18F-FDG PET/CTand the metabolic heterogeneity of PC, it should 
be considered together with other cancer or receptor-specific radiopharmaceutical agents such as 
radiolabelled choline and/or PSMA. Each imaging scan should be repeated, as suggested by the 
PCWG2, at the end of antitumour therapy unless more frequent assessments are required by the 
treatment protocol (2 – 3 months) or by the development of signs or symptoms suggesting tumour 
progression, or if a flare reaction is suspected. In these cases, it should be repeated after 3 months. 
On the other hand, in patients with non-bone-dominant disease 18F/11C-choline PET/CT and CT 
should preferably be used for follow-up, since radiolabelled choline scan can visualize both visceral 
and skeletal lesions, while CT is adequate to follow visceral lesions, especially those in the liver. If 
more accurate skeletal evaluation is required, MRI or 18F-fluoride PET/CT can be substituted for 
CT. In this subset of patients, radiolabelled choline PET/CT should be used during therapy (every 3 
– 6 months according to PCWG2 and the recent recommendations of the St. Gallen Consensus 
Conference [63, 139]) and at the end of therapy, or on the basis of changes in PSA level. 18F-
Choline PET/CT should be repeated within 3 months if a flare phenomenon is suspected (as 
described during abiraterone treatment). Lastly, there are two main advantages of including nuclear 
medicine imaging in monitoring the response to therapy in PC patients: to evaluate the effects of 
different targeting therapies on the metabolism of PC cells and to assess the state of the disease in 
relation to the timing of treatments.  
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Table 1 
Performance of radiological techniques in assessing the presence of bone metastases in patients 
with prostate cancer 
Technique Reference 
No. of 
patients 
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
predictive 
value (%) 
Accuracy 
(%) 
Plain 
radiography 
(add-on to bone 
scan) 
[77] 66 63 64 100 70 – 
[78] 14 58.6 – – – – 
[79] 100 86 98 98 87 – 
Weighted 
mean 
  75.4 84.5 98.8 80.2 NE 
Total 180           
CT (add-on to 
bone scan) 
[80] 15 67 – – – – 
MRI axial 
skeleton only 
[79] 66 100 88 100 100 – 
[80] 15 93 – – – – 
Weighted 
mean 
  98.7 NE NE NE NE 
Total 81           
Whole-body 
MRI with 
diffusion-
weighted 
imaging 
[80] 15 100 – – – – 
[78] 14 96.4 – – – – 
[81] 39 70 100 100 – – 
[82] 49 100 87.2 – – – 
[83] 35 91 99 97 97 – 
[84] 49 100 98 83 100 98 
[79] 100 98 98 98 98 – 
[85] 23 80 98.2 – – – 
Weighted 
mean 
  93.2 96.6 94.9 98.3 NE 
Total 324           
– not reported, NE not evaluated 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Performance of nuclear imaging techniques in patients with prostate cancer 
Technique Reference 
No. of 
patients 
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
predictive 
value (%) 
Accuracy 
(%) 
Bone scan 
[103] 91 65.4 38.5 86.4 15.6 61.5 
[104] 50 50.8 82.2 86.4 42.9 60.6 
[97] 44 57 57 59 55 – 
[105] 18 87.5 80 – – – 
[106] 72 96.9 41.2 75.6 87.5 77.5 
[107] 97 96.4 75.3 98.1 61.4 – 
[108] 10 66.7 81.6 53.3 88.6 78 
[109] 37 89.3 – – – – 
Weighted 
mean 
  78.5 59.3 83.2 52.5 67.2 
Total 419           
SPET 
[97] 44 78 67 72 74 – 
[107] 97 96.4 63.7 97.8 51.9 – 
Weighted 
mean 
  90.7 64.7 89.7 58.8 NE 
Total 141           
SPET/CT [107] 97 96.4 94.2 98.5 87.1   
18
F-Fluoride 
PET/CT 
[104] 50 93.1 54 81.8 77.9 81 
[97]
a
 44 100 62 74 100 – 
[97]
b
 44 100 100 100 100 – 
[110] 38 81 93 – – 86 
[111] 42 91 83 – – 88 
[105] 18 100 100 – – – 
[106] 72 100 70.6 86.5 100 65.4 
[108] 10 100 89.5 75 100 92 
Weighted 
mean 
  95.5 77.4 85.1 94.9 78.5 
Total 318           
18
F-FDG 
PET/CT 
[105] 18 55.6 80 – – – 
[106] 72 71.9 100 100 65.4 81.6 
Weighted 
mean 
  68.6 96 NE NE NE 
Total 90           
18
F-Choline 
PET/CT 
[110] 70 79 97 84 – – 
[112] 26 96 100 – – – 
[104] 50 84.7 91.1 95 74.9 86.8 
[113] 38 74 99 – – 88 
Technique Reference 
No. of 
patients 
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
predictive 
value (%) 
Accuracy 
(%) 
[111] 42 91 89 – – 90 
[109] 37 82.7 – – – – 
Weighted 
mean 
  83.5 94.9 88.6 NE 88.2 
Total 263           
11
C-Choline 
PET/CT 
[114] 25 86 100 – – – 
[103] 91 96 92.3 98.7 80 95.6 
[115] 78 89 98 96 94 95 
[116] 95 81.3 98.7 – – 95.8 
Weighted 
mean 
  88.4 96.6 97.5 86.5 95.5 
Total 289           
– not reported, NE not evaluated 
a
PET 
b
PET/CT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
Advantages and disadvantages of radiological and nuclear medicine techniques for detection and 
follow-up of bone metastases 
Technique Advantages Disadvantages 
Plain radiography 
1. High availability 
2. Low cost 
3. Easy for the patient 
4. Allows assessment of 
complications (e.g. fractures) 
1. Low sensitivity and specificity 
2. Not all bones can be screened 
3. Does not allow assessment of 
therapeutic response 
CT 
1. High availability 
2. Allows assessment of fine bone 
details and characterization smaller 
lesions 
3. Allows detection of node and 
visceral metastases 
1. High radiation dose 
2. Not used for systematic bone 
screening 
3. Not useful in assessment of therapy 
response 
MRI axial skeleton 
only 
1. Good availability 
2. Earlier detection of tumour foci 
3. Better diagnostic performance in 
detection and characterization of bone 
lesions 
1. Bone metastases outside vertebral 
column or pelvic bones not detected 
2. Not used for detection of node or 
visceral metastases 
3. Not useful in assessment of therapy 
response 
MRI with whole-
body and diffusion-
weighted 
acquisitions 
1. Highest diagnostic performance in 
detection and characterization of bone 
lesions 
2. Allows detection and assessment of 
therapeutic response of node and 
visceral metastases 
3. Possible role of diffusion-weighted 
and anatomic imaging (3D T1-
weighted) in assessment of therapeutic 
response 
1. Advanced diagnostic techniques only 
available in specialist diagnostic 
imaging centres 
2. Longer duration of examination 
3. Higher cost 
Bone scan 
1. Low cost [104] 
2. High availability [104] 
3. Able to detect bone metastases 
several months before they are 
revealed by plain radiography 
1. Low sensitivity for osteolytic lesions 
[97] 
2. No detection of bone marrow disease 
3. Poor sensitivity for osteolytic lesions 
without bone remodelling 
Technique Advantages Disadvantages 
4. Low specificity (false-positive 
findings in case of degenerative 
changes, inflammatory processes, 
trauma, mechanical stress, and Paget’s 
disease) [97] 
5. Bone reactive changes necessary for 
optimal sensitivity [104] 
6. Flare phenomenon due to some 
systemic treatments (also 
223
Ra) [128] 
SPET 
1. Improves the sensitivity of planar 
images 
1. Limited field of view [97] 
2. Specificity not better than plain 
radiography 
3. As bone scan (see above) [97] 
SPET/CT 
1. Improves the sensitivity of planar 
images 
2. Improves the specificity of planar 
images [97] 
1. Whole-body imaging not currently 
standard practice 
2. Resource implications of increased 
cost, specialist equipment, and 
specialist manpower hours 
3. Higher radiation dose than bone scan 
(3 – 5 mSv) 
4. As bone scan (see above) 
18
F-Fluoride 
PET/CT 
1. Elimination of fluoride from the 
blood is rapid. First pass elimination 
is 100 % vs. 64 % for diphosphonates 
2. Superior image quality and 
therefore high diagnostic accuracy 
[105] 
3. Rapid acquisition protocol (15 or 
60 min after injection) 
4. As 
99m
Tc-diphosphonate, is able to 
identify high bone turnover and 
remodelling 
5. Quantitative and automatic 
semiquantitative analyses of uptake in 
lesions [102] 
1. Very sensitive to minimal 
degenerative changes 
2. Higher cost and radiation dose 
compared with bone scan (from 3 to 5 –
 7 mSv) [97] 
3. Uncertain clinical impact when used 
to monitor treatment response 
4. Flare phenomenon due to some 
systemic treatments (also 
223
Ra) [127] 
18
F-FDG PET/CT 
1. Can detect bone metastases at early 
stage of disease (bone marrow 
1. Sclerotic metastases can be missed 
because of relatively small amount of 
Technique Advantages Disadvantages 
involvement) 
2. In osteolytic lesions and in presence 
of aggressive prostatic cancer, 
accumulation of tracer is higher for an 
increase in glycolytic rate [106] 
3. Lack of FDG uptake in the 
osteoblastic lesion can be associated 
with the presence of quiescent cells 
4. Superior image quality and 
therefore high diagnostic accuracy 
5. Prognostic information [129] 
6. Quantitative and automatic 
semiquantitative analyses of uptake in 
lesions [102] 
viable tumour tissue [126] 
2. FDG uptake limited in moderately or 
well-differentiated prostate cancer by 
low metabolism of the tissue [126] 
3. Higher cost and increased radiation 
dose compared with bone scan (from 3 
to 5 – 7 mSv) 
11
C/
18
F-Choline 
PET/CT 
1. More specific for prostate cancer 
2. Able to identify three patterns of 
bone disease (bone marrow 
involvement, osteoblastic lesions, no 
active tumour) [110] 
3. No uptake in chronic degenerative 
disease 
4. Quantitative and automatic 
semiquantitative analyses of uptake in 
lesions [102] 
1. Flare phenomena reported during 
administration of abiraterone acetate 
and granulocyte-colony stimulating 
factor [121] 
2. 
11
C-Choline not available in centres 
without on-site cyclotron 
3. High cost and increased radiation 
dose compared with bone scan (from 3 
to 5 – 7 mSv) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 
Performance of 
68
Ga-PSMA PET in the detection of bone metastases 
Reference No. patients PSA level
a
 (ng/mL) 
Bone metastasis detection 
Detection rate Sensitivity (%) 
[132] 5 – – Not available 
[130] 319 4.59 (0.01 – 41,395) 359/901 Not available 
[96] 37 4.0 (0.01 – 116) 23/78 Not available 
[133] 38 1.72 ± 2.54 10/59 Not available 
[131] 20 2.62 (0.51 – 73.6) 23/75 Not available 
All 419 – 415/1,113 (37 %)b – 
a
Expressed as median (range) or mean ± standard deviation, in accordance with available data 
b
A lesion-based analysis was available in all studies 
Table 5 
Performance of radiolabelled choline PET in the detection of bone metastases 
Reference No. of patients PSA level
a
 (ng/mL) 
Bone metastasis detection 
Detection rate Sensitivity (%) 
[137] 48 12.71
b
 (2.80 – 581) 14 100 
[134] 102 0.93 (0.67 – 1.10) 13 100 
[138] 132 7.2 (2.2 – 1028) 26 Not available 
[115] 78 2.4 (0.2 – 500) 24 89 
[135] 140 4.9 (0.2 – 92) 70 Not available 
[136] 1,000 3.30 (0.2 – 10,960) 335 80 (in 235 patients) 
All 1,500 – 482 (32.1 %)c – 
a
Expressed as median (range) or mean ± standard deviation, in accordance with available data 
b
The study was performed at initial staging of disease 
c
A patient-based analysis was available in all studies 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Whole-body MR images in a 69-year-old man with diffuse metastatic bone disease and signs of progression during 
antiandrogenic therapy. MR protocol corresponding whole-body 3D T1-weighted, STIR (short-tau inversion recovery) and diffusion-
weighted images. Total scan time 54 min. a 3D coronal T1-weighted images with reconstructed sagittal and axial planes showing 
bone metastases as multiple hypointense foci involving vertebrae, ribs, hip, sternum and femurs. Early progression of disease is 
represented by the appearance of low signal intensity tissue adjacent to some of these foci (e.g. L2 and right iliac bone). b 
Corresponding STIR images confirm the predominantly osteosclerotic nature of the metastases which appear mostly hypointense; 
early progression of metastatic involvement is represented by the appearance of moderately high signal intensity bone changes. C 
DW images with 3D maximum intensity projection reconstruction identify early progression of disease as appearance of hyperintense 
bone foci representing tissue with restricted diffusion due to high cellularity. The remaining bone metastases are not clearly seen on 
the DW images, representing false-negative findings due to advanced sclerotic changes inside the lesions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 
A 68-year-old man with prostate cancer treated by radical prostatectomy (pT3aN0Mx, Gleason 
score 10; positive margins and extracapsular invasion) and adjuvant radiotherapy in 2010. May 
2012 In 2012, for biochemical recurrence of disease (PSA 15.55 ng/mL), he was staged by 
18
F-
choline PET/CT that showed metastatic bone recurrence of disease. He was started on bicalutamide 
and LHRH analogues. October 2012 Due to a further increase in PSA (141 ng/mL after 4 months), 
18
F-choline PET/CT was repeated that showed progression of metabolic disease. Therefore, the 
attending oncologist suggested switching the treatment from androgen deprivation therapy to 
chemotherapy (docetaxel + prednisone). February 2013 After 4 months, PSA had reduced to 
33.6 ng/mL and 
18
F-choline PET/CT showed a good response to chemotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3  
Diagnostic algorithm proposed for assessment of response to therapy in patients with metastatic 
prostate cancer (well-differentiated or low-risk prostate cancer is considered to be present in 
patients with a Gleason score of 6, moderately differentiated or intermediate-risk prostate cancer in 
patients with a Gleason score of 7, and poorly differentiated or high-risk prostate cancer in patients 
with a Gleason score of between 8 and 10) wMRI whole-body MRI 
 
